234 related articles for article (PubMed ID: 32914146)
21. Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis.
George EV; Pharm J; Houston C; Al-Quran S; Brian G; Dong H; Hai W; Reeves W; Yang LJ
Int J Clin Exp Pathol; 2013; 6(8):1631-42. PubMed ID: 23923082
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
Foyil KV; Bartlett NL
Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
[TBL] [Abstract][Full Text] [Related]
23. Breast Implant-associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms.
Sharma B; Jurgensen-Rauch A; Pace E; Attygalle AD; Sharma R; Bommier C; Wotherspoon AC; Sharma S; Iyengar S; El-Sharkawi D
Radiographics; 2020; 40(3):609-628. PubMed ID: 32302264
[TBL] [Abstract][Full Text] [Related]
24. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G
Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736
[TBL] [Abstract][Full Text] [Related]
25. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.
Donato EM; Fernández-Zarzoso M; Hueso JA; de la Rubia J
Onco Targets Ther; 2018; 11():4583-4590. PubMed ID: 30122950
[TBL] [Abstract][Full Text] [Related]
27. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review.
Leberfinger AN; Behar BJ; Williams NC; Rakszawski KL; Potochny JD; Mackay DR; Ravnic DJ
JAMA Surg; 2017 Dec; 152(12):1161-1168. PubMed ID: 29049466
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.
Lowe EJ; Reilly AF; Lim MS; Gross TG; Saguilig L; Barkauskas DA; Wu R; Alexander S; Bollard CM
Blood; 2021 Jul; 137(26):3595-3603. PubMed ID: 33684925
[TBL] [Abstract][Full Text] [Related]
29. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
30. Breast implant-associated anaplastic large cell lymphoma: a review.
Quesada AE; Medeiros LJ; Clemens MW; Ferrufino-Schmidt MC; Pina-Oviedo S; Miranda RN
Mod Pathol; 2019 Feb; 32(2):166-188. PubMed ID: 30206414
[TBL] [Abstract][Full Text] [Related]
31. UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG).
Turton P; El-Sharkawi D; Lyburn I; Sharma B; Mahalingam P; Turner SD; MacNeill F; Johnson L; Hamilton S; Burton C; Mercer N
Eur J Surg Oncol; 2021 Feb; 47(2):199-210. PubMed ID: 33358076
[TBL] [Abstract][Full Text] [Related]
32. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
34. Breast Implant-associated Anaplastic Large Cell Lymphoma Affecting a Neosubpectoral Pocket.
Hobson G; Bates J; Sherbert D
Cureus; 2020 Mar; 12(3):e7178. PubMed ID: 32257718
[TBL] [Abstract][Full Text] [Related]
35. Breast Implant-Associated Anaplastic Large Cell Lymphoma Presenting in a Postpartum Patient: A Case Report.
Al-Shaikhli SA; Mautner S; Nasseri-Nik N; Lampen-Sachar K
Cureus; 2023 Aug; 15(8):e43334. PubMed ID: 37700989
[TBL] [Abstract][Full Text] [Related]
36. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
Chen X; Soma LA; Fromm JR
Onco Targets Ther; 2013 Dec; 7():45-56. PubMed ID: 24379682
[TBL] [Abstract][Full Text] [Related]
38. IL-13 is produced by tumor cells in breast implant-associated anaplastic large cell lymphoma: implications for pathogenesis.
Kadin ME; Morgan J; Xu H; Epstein AL; Sieber D; Hubbard BA; Adams WP; Bacchi CE; Goes JCS; Clemens MW; Medeiros LJ; Miranda RN
Hum Pathol; 2018 Aug; 78():54-62. PubMed ID: 29689246
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
40. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
Garnock-Jones KP
Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
